Ruxolitinib for Vitiligo Approved for Marketing in EU
Last year in the United States, the topical JAK inhibitor became the first repigmentation treatment approved by the FDA for nonsegmental vitiligo, the most common form of the disease.
Medscape Medical News
source https://www.medscape.com/viewarticle/991047?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/991047?src=rss
Comments
Post a Comment